Deaths and disability from natalizumab are no longer tolerable: No-(they can be avoided)

Multiple Sclerosis Journal

Volumn 18, Issue 8, 2012, Pages 1070-1072

  Sørensen, Per Soelberg ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; NATALIZUMAB; VIRUS ANTIBODY;

ARTICLE; BLOOD CHEMISTRY; CLINICAL PROTOCOL; DISABILITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; MORTALITY; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SAFETY; PLASMAPHERESIS; PRACTICE GUIDELINE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEROCONVERSION; TREATMENT DURATION;

EID: 84864139314     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512451946     Document Type: Article

References (10)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
2. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 911-923
3. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005 ; 353: 369-374
4. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005 ; 353: 375-381
5. Kean JM, Rao S, Wang M, et al. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009 ; 5: e1000363
6. Sunyaev SR, Lugovskoy A, Simon K, et al. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet. 2009 ; 5: e1000368
7. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010 ; 68: 295-303
8. Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012 ; 18: 143-152
9. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011 ; 10: 745-758
10. Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011 ; 76: 1697-1704